ECHODIA...
As many business company, ECHODIA was born of a meeting or rather the result of a meeting between two persons with diverse skills and experiences in the fields of medical and electronics.
Indeed it was in 2005 that Professor Paul AVAN of the Biophysics and Sensory Laboratory of Clermont-Ferrand met Thierry HASSOUN, an electronics engineer. The first goal of this merger was initially to build a device thanks to the work research of Professor AVAN on the diagnosis of intra-cochlear hydrops.
Following several years of incubation in the laboratory of Professor AVAN, and after winning by several times (2006 and 2008) the national price for the creation of innovative technology companies, Thierry HASSOUN founded in February 2009 the ECHODIA Company.
Today ECHODIA is specializing in the development of non-invasive medical device in the ways of Otorhinolaryngology and Neurosciences. By exploiting the technology developed by Professor Paul AVAN, the company has designed a device for the investigation of the inner ear pathology which no reliable diagnostic existed until now for Meniere's disease.
With a unique know-how in the field of ENT thanks to its collaboration with the Biophysics and Sensory Laboratory of Clermont-Ferrand and skills of its Research Department, ECHODIA is now able to be the new supplier of ENT doctors, thanks to continuous innovation it brings to its ELIOS device.
ABOUT OUR PATENTED TECHNOLOGY...
As seen before through the work of Professor AVAN, ECHODIA now develop and commercialize in its product range, two tests for the diagnosis of the intra-cochlear hydrops named DDPOAE and DPMC.
- The DDPOAE: Phase Shift of Distortion Product of Otoacoustic Emissions.
The DDPOAE are a measure which is only realized by ECHODIA in the field of ENT. This measures the phase shift of cochlear emissions around 1000 Hz. With a postural test realized in 3 stages on the patient (record responses on the patient in standing position, after record responses in lying down position and finally back to the original standing position) the DDPOAE, when there are present on patients, determine precisely the presence or no of intra-cochlear hydrops which is the signature of Meniere's disease.
-
The DPMC: Phase Shift of the Microphonic Cochlear Potential.
In addition to the DDPOAE and with its strong know-how and its collaboration with the Biophysics and Sensory Laboratory of Clermont-Ferrand, ECHODIA has developed a new method for measuring physiological inner ear, the Phase Shift of Microphonic Cochlear Potential (DPMC).
This unique and property measure of ECHODIA collects the electrical activity of outer hair cells of the cochlea after an acoustic stimulation by “ToneBurst”. This measure is protected by a patent.
It therefore allows detecting objectively Meniere's disease or no on patients, high lighting the intra-cochlear hydrops.
Note:
The DPMC and DDPOAE are complementary. These measures will allow us to objectively diagnose Meniere's disease. Indeed, the DPMC collect the electrical activity of outer hair cells while the DDPOAE collect acoustic activity of these cells.
For more information or quotation, please contact us:
Phone: +33 (0)4 73 27 49 82
Fax: +33 (0)4 73 27 49 33
e-mail to following address: contact@echodia.fr